IL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohort.

ABSTRACT:

Background

In breast cancer, high levels of the inflammatory cytokine interleukin-6 (IL-6) have been associated with disease-free survival and treatment resistance. Increased serum levels of IL-6 have been correlated with increased levels of NF-κβ and aromatase expression in adipose tissue. Several IL6 single nucleotide polymorphisms have been associated with breast cancer prognosis, but the impact may differ depending on tumour oestrogen receptor (ER) status. This translational study investigated the association between IL6 genotypes, ER-status, and treatment on the risk of early events among breast cancer patients.

Methods

The study included 634 25- to 99-year-old primary breast cancer patients in Sweden from 2002-2008. Genotyped IL6 single nucleotide polymorphisms rs18007

SUBMITTER: Markkula A 

PROVIDER: S-EPMC4198733 | biostudies-literature | 2014 Oct

REPOSITORIES: biostudies-literature